StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ORKA yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q2 2024 2024-06-30 | Q1 2024 2024-03-31 | Annual 2023 2023-12-31 | Q3 2023 2023-09-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-28.36M | $-6.86M | $-7.30M | $-5.71M |
Net Income | $-29.32M | $-7.08M | $-1.09M | $-1.42M |
EPS (Diluted) | $-9.17 | $-2.21 | $-0.37 | $-0.29 |
Total Assets | $33.84M | $36.71M | $37.86M | $39.18M |
Total Liabilities | $1.27M | $1.58M | $841.00K | $1.22M |
Cash & Equivalents | $33.28M | $35.90M | $37.43M | $38.49M |
Free Cash Flow OCF − CapEx | Not available | Not available | $-5.01M | Not available |
Shares Outstanding | 14.51M | 14.50M | 14.50M | 14.41M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $62.50 | $61.93 | -0.91% | 1.4M |
| 05-18 | $62.00 | $58.34 | -5.90% | 1.9M |
| 05-19 | $57.00 | $57.50 | +0.88% | 2.3M |
| 05-20 | $58.68 | $60.67 | +3.39% | 1.4M |
| 05-21 | $59.56 | $58.25 | -2.20% | 0.4M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.